Quarterly report pursuant to Section 13 or 15(d)

STOCKHOLDERS' DEFICIT (Details Narrative)

STOCKHOLDERS' DEFICIT (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended
STOCKHOLDERS' DEFICIT (Details Narrative) - USD ($)	Jan. 22, 2019	Mar. 31, 2019	Dec. 31, 2018	Dec. 30, 2018	Nov. 15, 2018	May 10, 2018	May 09, 2018	Jan. 26, 2018
Preferred stock, shares authorized		600,000	600,000
Preferred stock, shares issued		80,000	80,000
Preferred stock, shares outstanding		80,000	80,000
Common stock exchange description	As a result, 259,984,655 shares of the Company’s common stock were exchanged for 2,599,847 shares of the Company’s common stock.
Reverse stock split	The ratio of 1 share for every 100 shares of common stock.
Common stock, shares authorized		750,000,000	750,000,000			750,600,000	525,000,000
Common stock, par value per share		$ 0.001	$ 0.001			$ 0.001
Common stock, shares issued		3,030,124	2,597,347		2,500			100,000
Common Stock, shares outstanding		3,030,124	2,597,347
Common stock shares issued for services, shares		8,706
Common stock shares issued for services, value		$ 40,250
Common stock issued in connection with note payable extension, Amount		$ 7,500
Series B Preferred Stock [Member]
Preferred stock, shares issued		160,000	160,000	160,000
Preferred stock, shares outstanding		160,000	160,000	160,000
Common Stock
Common stock issued in connection with note payable extension, Shares		1,000
Common stock issued in connection with note payable extension, Amount		$ 1
Royalty Agreement [Member]
Subscription receivable		$ 1,560,000
Common stock, shares issued		400,000
Louis and Carolyn Lucido CRT LLC [Member]
Subscription and royalty agreement description		Pursuant to the Subscription and Royalty Agreements: (i) Each party would purchase shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), in the aggregate amount of $3,000,000 at a purchase price of $15.00 per share (the “Purchase Price”), for a total of 200,000 shares of Common Stock; and (ii) the Company shall pay each (a) a total of $37.50 from the gross revenue derived from each of its weight loss treatments sold in the United States starting on the first (1st) day that the first unit of the treatment is sold (the “Initial Sales Date”) and ending on the third (3rd) anniversary of the Initial Sales Date; and (b) a total of $25.00 from the gross revenue derived from each of its weight loss treatments sold in the United States starting on the day following the third (3rd) anniversary of the Initial Sales Date and ending on the fifteenth (15th) anniversary of the Initial Sales Date (the “Royalty”).
Description for the use of proceeds under agreement		Under the Lucido agreement, the Company will use no less than 65% of the proceeds of the aggregate Purchase Price of the Lucido Subscription and Royalty Agreement exclusively to develop, launch and expand the Company’s weight loss program (the “Business”) including sales and marketing activities directly related to the Business, and shall be free to use up to 35% of the aggregate Purchase Price of the Lucido Subscription and Royalty Agreement for general working capital and administration, and for further product development. With the prior written consent of Mr. Lucido, the Company may use more than 35% of the aggregate Purchase Price for general working capital and administration, and for further product development.